Komori
Transgenic Group (2342) · RiskRestated

Risk of Changes in the Direction of Joint Research and Rights Arrangements

First written in FY2016. 4 of 5 entries say "Restated". Latest entry: FY2026.

5entries
11years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2016 – FY20262016: 120162017: 120172018: 020182019: 120192020: 120202021: 020212022: 020222023: 020232024: 020242025: 020252026: 12026
Same theme, other companies
Dependence on Alliance Partners' Technology, R&D and Management PoliciesA theme 27 companies write about · 29 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2025: 3 of 9 companies on the "Worse" side.

10 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 27 companies compared. The sentences above are computed from all 27.
Full recordFilings, disclosures and news, newest first
  1. FY2026RestatedAnnual report

    「The Company conducts joint research with public research institutions, universities and other institutions, but relationships between companies and public research institutions may be affected by amendments to laws and regulations or organizational changes.」

    The Company reconfirms the risk of changes in the direction of and ownership of rights relating to joint research with public research institutions and universities as a result of amendments to laws and organizational changes.
  2. FY2020RestatedAnnual report

    「Relationships between companies and public research institutions may be affected by amendments to laws and regulations or organizational changes. Accordingly, if such changes make changes in the direction of joint research or ownership of rights unavoidable, this may affect the Company's business strategy and performance.」

    The Company reiterates the risk of changes in the direction of joint research and ownership of rights involving public research institutions and universities as a result of amendments to laws and organizational changes.
  3. FY2019RestatedAnnual report

    「Relationships between companies and public research institutions may be affected by amendments to laws and regulations or organizational changes. If changes in the direction of joint research or ownership of rights become unavoidable, this may affect the Company's business strategy and performance.」

    The Company reiterates the risk of changes in the direction of and ownership of rights relating to joint research with public research institutions and universities.
  4. FY2017RestatedAnnual report

    「Relationships between companies and public research institutions may be affected by amendments to laws and regulations or organizational changes. If changes in the direction of joint research or ownership of rights become unavoidable, this may affect the Company's business strategy and performance.」

    The Company reiterates the risk of changes in the direction of joint research and ownership of rights involving public research institutions and universities.
  5. FY2016First statedAnnual report

    「Relationships between companies and public research institutions may be affected by amendments to laws and regulations or organizational changes. If changes in the direction of joint research or ownership of rights become unavoidable, this may affect the Company's business strategy and performance.」

    The Company identifies changes in the direction of joint research and ownership of rights resulting from amendments to laws and regulations or organizational changes as risks in its joint research with public research institutions and universities.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Transgenic Group yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Risk of Changes in the Direction of Joint Research and Rights Arrangements | TRANSGENIC GROUP INC. (2342) | Komori